Every material Form 8-K Corcept Therapeutics has filed with the SEC since April 17, 2024, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Corcept Therapeutics reported third quarter 2026 revenue of $340.5 million, up 64 percent from the same period in 2025, and net income of $126.8 million, compared with $19.7 million a year earlier. The company reiterated its 2026 revenue guidance of $1.1 billion to $1.2 billion, and its Lifyorli ovarian cancer product contributed $91.4 million of the quarter's revenue.
Q3 2026 revenue of $340.5 million vs. $207.6 million in Q3 2025; Korlym and authorized generic revenue was $249.1 million and Lifyorli revenue was $91.4 million
Q3 2026 net income of $126.8 million, or $1.01 per diluted share, vs. $19.7 million, or $0.16 per diluted share, in Q3 2025
2026 revenue guidance of $1.1 billion to $1.2 billion reiterated; cash and investments rose to $662.3 million at September 30, 2026
Relacorilant for Cushing's syndrome has a PDUFA date of December 17, 2026
Corcept Therapeutics said Sean Maduck, President of its Endocrinology division, will retire effective October 1, 2026, and Justin Gunn will succeed him. Maduck will stay on as a consultant under an agreement paying $57,000 per month, and the company said he did not resign because of any disagreement with the company. The filing does not include financial results or guidance changes, so the direct effect on shareholders is limited to the leadership change.
Sean Maduck notified the board on September 22, 2026 of his decision to resign effective October 1, 2026.
Maduck's consulting agreement runs through September 30, 2027, with a cash fee of $57,000 per month, and his outstanding stock options continue to vest.
Justin Gunn joined Corcept in July 2024 as Vice President of Sales and Commercial Learning for the Oncology division and will report to CEO Joseph K. Belanoff, M.D.
Corcept Therapeutics reported second-quarter 2026 revenue of $256.1 million, up 32% from $194.4 million a year earlier, and raised its 2026 revenue guidance to $1.1-$1.2 billion. Net income rose to $43.0 million from $35.1 million, though operating expenses increased to $214.8 million from $167.8 million on Lifyorli launch spending and Cushing's syndrome investments.
Q2 2026 revenue of $256.1 million, including $47.6 million from Lifyorli in its first quarter of availability
Diluted net income per share of $0.36, compared with $0.29 in Q2 2025
Operating expenses rose to $214.8 million from $167.8 million, driven by Lifyorli launch and Cushing's investments
Six-month net income was $11.2 million, down from $55.7 million a year earlier; the FDA decision on the Cushing's NDA is expected by December 17, 2026
At its May 21, 2026 annual meeting, Corcept Therapeutics stockholders approved an amendment adding 8,000,000 shares to the 2024 Incentive Award Plan, which took effect that day. The filing also reports the election of eight directors and the ratification of Ernst & Young LLP as the independent auditor for fiscal 2026. The plan increase expands the shares available for equity awards, which can dilute existing holders.
Stockholders approved the Amended 2024 Incentive Award Plan, adding 8,000,000 shares, with 53,163,364 votes for, 23,867,363 against and 263,730 abstaining.
All eight director nominees were elected to serve until the 2027 annual meeting, including Joseph K. Belanoff, M.D., and David L. Mahoney.
Ernst & Young LLP was ratified as the independent registered public accounting firm for the year ending December 31, 2026, with 92,656,473 votes for.
In an advisory vote, stockholders approved named executive officer compensation, with 72,511,429 votes for and 4,560,385 against.
Corcept reported first quarter 2026 revenue of $164.9 million, up from $157.2 million a year earlier, but swung to a net loss of $31.8 million from net income of $20.5 million, as operating expenses rose to $214.5 million from $153.8 million. The company raised its 2026 revenue guidance to $950 million to $1,050 million and said it expects to return to profitability in the second quarter of 2026.
Revenue was $164.9 million versus $157.2 million in Q1 2025; diluted net loss per share was $0.30 versus diluted earnings of $0.17.
Operating expenses were $214.5 million versus $153.8 million, driven by spending to prepare for the Lifyorli launch and growth initiatives in the Cushing's syndrome business.
2026 revenue guidance was increased to $950 million to $1,050 million.
Cash and investments were $515.4 million at March 31, 2026, down from $532.4 million at December 31, 2025.
Corcept reported fourth quarter and full-year 2025 results with revenue up from 2024 but net income and diluted earnings per share down. The company also gave 2026 revenue guidance of $900 million to $1,000 million, and said its Cushing's syndrome business was constrained by specialty pharmacy capacity and a fourth-quarter pharmacy transition.
Full-year 2025 revenue was $761.4 million, up from $675.0 million in 2024.
Full-year 2025 net income was $99.7 million, or $0.82 diluted per share, down from $141.2 million, or $1.23 diluted per share, in 2024.
Fourth-quarter 2025 revenue was $202.1 million, up from $181.9 million; fourth-quarter net income was $24.3 million, or $0.20 diluted per share, down from $30.7 million, or $0.26.
Full-year 2026 revenue guidance is $900 million to $1,000 million; cash and investments were $532.4 million at December 31, 2025.
Corcept Therapeutics reported third quarter 2025 revenue of $207.6 million, up from $182.5 million a year earlier, but net income fell to $19.7 million from $47.2 million as operating expenses rose to $197.4 million. The company also modified its 2025 revenue guidance to $800 million to $850 million and said it added a new specialty pharmacy on October 1 to meet demand for Korlym.
Q3 2025 revenue was $207.6 million, compared with $182.5 million in Q3 2024.
Q3 2025 net income was $19.7 million, compared with $47.2 million; diluted EPS was $0.16, compared with $0.41.
Operating expenses were $197.4 million, compared with $135.9 million, reflecting spending to prepare for launches of relacorilant.
2025 revenue guidance was modified to $800 million to $850 million; the NDA for relacorilant in hypercortisolism has a PDUFA date of December 30, 2025.
Corcept director Gillian Cannon, Ph.D., notified the board on October 6, 2025 that she will resign effective October 10, 2025, and she did not cite any disagreement with the company. She will continue as a consultant to the board under a Consulting Services Agreement through the 2026 stockholder meeting, with her outstanding stock options continuing to vest, so the change is limited in scope for shareholders.
Resignation from the board effective October 10, 2025; no disagreement with the company cited
Consulting Services Agreement runs from the effective date until the 2026 stockholder meeting
Cash fee of $5,708.33 per month under the consulting agreement
Previously awarded stock options continue to vest on their original schedules
Corcept reported second quarter 2025 revenue of $194.4 million, up from $163.8 million a year earlier, but net income was $35.1 million versus $35.5 million and diluted earnings per share fell to $0.29 from $0.32. The company modified its 2025 revenue guidance to $850 million to $900 million and said demand outpaced its specialty pharmacy vendor's capacity, which it expects to ease as a second pharmacy comes online.
Q2 2025 revenue $194.4 million vs. $163.8 million in Q2 2024
Net income $35.1 million vs. $35.5 million; diluted EPS $0.29 vs. $0.32
Selling, general and administrative expense $103.9 million vs. $66.9 million a year earlier
2025 revenue guidance modified to $850 million to $900 million; cash and investments $515.0 million at June 30, 2025
Corcept reported first quarter 2025 revenue of $157.2 million, up from $146.8 million a year earlier, but net income fell to $20.5 million and diluted earnings per share fell to $0.17 from $0.25. The company reiterated its 2025 revenue guidance of $900 million to $950 million and said a specialty pharmacy vendor's capacity limits hurt first quarter results.
Revenue was $157.2 million versus $146.8 million in first quarter 2024.
Operating expenses rose to $153.8 million from $117.3 million, with selling, general and administrative expenses at $90.7 million versus $56.3 million.
2025 revenue guidance of $900 million to $950 million was reiterated.
Cash and investments were $570.8 million at March 31, 2025, down from $603.2 million at December 31, 2024.
Corcept Therapeutics reported fourth-quarter and full-year 2024 results and gave a corporate update in a press release attached to this 8-K. Full-year 2024 revenue rose to $675.0 million from $482.4 million and full-year net income rose to $141.2 million, while fourth-quarter net income and diluted earnings per share were slightly lower than a year earlier. The company also gave 2025 revenue guidance of $900-950 million.
Q4 2024 revenue was $181.9 million, compared with $135.4 million in Q4 2023.
Q4 2024 net income was $30.7 million, or $0.26 diluted per share, versus $31.4 million, or $0.28, in Q4 2023.
Full-year 2024 net income was $141.2 million, or $1.23 diluted per share, versus $106.1 million, or $0.94, in 2023.
Cash and investments were $603.2 million at December 31, 2024; company expects ROSELLA pivotal trial data in the current quarter.
Corcept reported third-quarter 2024 revenue of $182.5 million, up 48% from a year earlier, and net income of $47.2 million. The company raised its full-year 2024 revenue guidance to $675 million-$700 million, from $640 million-$670 million, and said Phase 3 GRADIENT trial results support its planned new drug application for relacorilant in Cushing's syndrome.
Q3 2024 revenue $182.5 million vs. $123.6 million in Q3 2023
Diluted net income per share $0.41 vs. $0.28 a year earlier
2024 revenue guidance raised to $675 million-$700 million from $640 million-$670 million
Relacorilant NDA submission for Cushing's syndrome expected this quarter; cash and investments $547.6 million at September 30, 2024
Corcept Therapeutics reported second-quarter 2024 revenue of $163.8 million, up 39% from a year earlier, and raised its full-year 2024 revenue guidance to $640 million to $670 million from $620 million to $650 million. Diluted earnings per share were $0.32, compared with $0.25 in the second quarter of 2023, though operating expenses rose to $128.2 million from $88.1 million.
Q2 2024 revenue of $163.8 million, versus $117.7 million in Q2 2023
Diluted EPS of $0.32 versus $0.25; net income of $35.5 million versus $27.5 million
2024 revenue guidance raised to $640 million to $670 million from $620 million to $650 million
Cash and investments of $492.5 million at June 30, 2024, up from $451.0 million at March 31, 2024
At its May 17, 2024 annual meeting, Corcept's stockholders approved the 2024 Incentive Award Plan, which replaces the 2012 Plan. The filing also reports the election of nine directors, the ratification of Ernst & Young LLP as auditor for 2024, and an advisory approval of executive compensation. The new plan sets the share pool for equity awards going forward.
The 2024 Plan reserves 8,000,000 shares, plus 4,073,955 shares available under the 2012 Plan as of May 17, 2024, plus any shares from lapsed 2012 Plan awards.
Plan approval vote: 47,018,093 for, 18,698,799 against, 161,233 abstentions, with 22,496,239 broker non-votes.
All nine director nominees were elected to serve until the 2025 annual meeting.
Stockholders ratified Ernst & Young LLP for the fiscal year ending December 31, 2024, with 86,596,528 votes for and 1,707,066 against.
Corcept Therapeutics reported first quarter 2024 revenue of $146.8 million, up 39 percent from a year earlier, and net income of $27.8 million, compared with $15.9 million in the first quarter of 2023. The company raised its 2024 revenue guidance to $620 million to $650 million from $600 million to $630 million, which points to stronger expected sales for the year.
Q1 2024 revenue of $146.8 million vs. $105.7 million in Q1 2023; diluted EPS $0.25 vs. $0.14
2024 revenue guidance raised to $620 million to $650 million from $600 million to $630 million
Operating expenses rose to $117.3 million from $90.8 million, driven by clinical trial activity and commercial team expansion
Cash and investments were $451.0 million at March 31, 2024, up from $425.4 million at December 31, 2023
Corcept Therapeutics entered into a sublease on April 12, 2024 for about 50,632 rentable square feet at 101 Redwood Shores Parkway in Redwood City, California, with the sublessor Zuora, Inc. The lease runs from about July 1, 2024 through June 30, 2030, creating a new direct financial obligation. The filing discloses base rent averaging $1.4 million a year plus $240,000 a year for shared amenities, a modest commitment that the filing does not compare with Corcept's financial results.
Sublease dated April 12, 2024 with Zuora, Inc. for about 50,632 rentable square feet
Term expected to start on or around July 1, 2024 and end June 30, 2030
Base rent averages $1.4 million annually, plus $240,000 annually for shared amenities space
Full sublease to be filed with a Form 10-Q; Corcept intends to seek confidential treatment for some terms
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Corcept Therapeutics filing is on SEC EDGAR ↗. 8-K briefs of other companies →